Dyne Therapeutics Q3 net loss $41.4M; Phase 1/2 trials for DM1 and DMD underway with data H2 2023

Dyne Therapeutics, Inc.

2022-Q3 EPS reported -$2.50

Net loss of $41.4M ($0.80 per share) vs $42.6M ($0.83) in Q3 2021; cash $248.1M funds operations through 2024.
R&D expense $34.7M, G&A $7.6M; R&D slightly down YoY.
ACHIEVE trial (DYNE-101 for DM1) and DELIVER trial (DYNE-251 for DMD) both enrolling; primary endpoints safety and tolerability.
DYNE-251 granted FDA Fast Track designation in October 2022.
Data from placebo-controlled portions of both trials anticipated in second half of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dyne Therapeutics, Inc. reported the third quarter of 2022 results: net income Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share., EPS $0.80 per basic and diluted share.

Period: the third quarter of 2022
Net income: Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share.
EPS: $0.80 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2022 was $41.4 million, or $0.80 per basic and diluted share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021556

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.